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Abstract
Background Tumor recurrence after radical resection of
hepatic tumors is not uncommon, suggesting that malignant
lesions are missed during surgery. Intraoperative naviga-
tion using fluorescence guidance is an innovative technique
enabling real-time identification of (sub)capsular liver
tumors. The objective of the current study was to compare
fluorescence imaging (FI) and conventional imaging
modalities for laparoscopic detection of both primary and
metastatic tumors in the liver.
Methods Patients undergoing laparoscopic resection of a
malignant hepatic tumor were eligible for inclusion.
Patients received standard of care, including preoperative
CT and/or MRI. In addition, 10 mg indocyanine green was
intravenously administered 1 day prior to surgery. After
introduction of the laparoscope, inspection, FI, and
laparoscopic ultrasonography (LUS) were performed.
Histopathological examination of resected suspect tissue
was considered the gold standard.
Results Twenty-two patients suspected of having hepato-
cellular carcinoma (n = 4), cholangiocarcinoma (n = 2) or
liver metastases from colorectal carcinoma (n = 12), uveal
melanoma (n = 2), and breast cancer (n = 2) were inclu-
ded. Two patients were excluded because their surgery was
unexpectedly postponed several days. Twenty-six malig-
nancies were resected in the remaining 20 patients. Sen-
sitivity for various modalities was 80 % (CT), 84 % (MRI),
62 % (inspection), 86 % (LUS), and 92 % (FI), respec-
tively. Three metastases (12 %) were identified solely by
FI. All 26 malignancies could be detected by combining
LUS and FI (100 % sensitivity).
Conclusion This study demonstrates added value of FI
during laparoscopic resections of several hepatic tumors.
Although larger series will be needed to confirm long-term
patient outcome, the technology already aids the surgeon
by providing real-time fluorescence guidance.
Keywords Tumor imaging  Surgical navigation 
Intraoperative guidance  Indocyanine green  Hepatic
metastases  Fluorescence imaging
Major advances have been achieved in the treatment of
patients with liver-only metastases and primary liver
tumors. Several studies and meta-analyses show improved
overall survival after aggressive resection [1–3]. Recur-
rence-free survival, however, is rather low. Up to 69 % of
patients with colorectal liver metastases develop local
recurrence or new metastases, with the majority in the first
year [4]. Similar rates are reported in patients undergoing
resection of hepatocellular carcinoma (HCC) [5]. These
numbers are not entirely explained by incomplete
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resections and support the hypothesis that small malignant
lesions are missed during resection.
It is well known that preoperative imaging modalities,
including computed tomography (CT) and magnetic reso-
nance imaging (MRI), have relatively low sensitivity for
sub-centimeter lesions due to their limited spatial resolu-
tion. Moreover, altered body position during surgery and
time interval between preoperative imaging and surgery
make translation of preoperative images challenging.
Extensive intraoperative inspection and palpation of the
liver is therefore of vital importance. Palpation, however, is
impossible during minimally invasive procedures.
Laparoscopic ultrasonography (LUS) can assist in detect-
ing tumors, but acoustic reflection artifacts can obscure
tumors in the first millimeters below the liver capsule [6].
In short, surgeons need a highly sensitive, real-time intra-
operative imaging modality to identify small superficial
tumors in the liver.
Ishizawa et al. [7] reported in 2009 that an intravenous
injection of the safe and widely used dye indocyanine
green (ICG) causes ‘‘bullseyes’’ of fluorescence to be
formed around primary or metastatic tumors in the liver.
Defective biliary clearance in the transition area between
tumor and normal liver tissue and in primary liver tumors
results in ICG retention, which can be visualized using a
near-infrared (NIR) fluorescence imaging system. Our
group showed that this method of detection is feasible
during resection of hepatocellular carcinoma (HCC) and
hepatic metastases of uveal melanoma (UMLM) and col-
orectal cancer (CRLM) [8–10]. The added value of fluo-
rescence imaging during oncological liver surgery is
twofold: (1) It can demarcate liver tumors and provide real-
time resection margin assessment, and (2) it can identify
otherwise undetectable, i.e., occult, (sub)capsular liver
tumors. NIR fluorescence imaging can be especially valu-
able during minimally invasive procedures, because sur-
geons are deprived of tactile feedback. Based on previous
study results, fluorescence imaging is now routinely per-
formed during laparoscopic liver surgery in our hospital if
patients provide informed consent. The purpose of the
present study was to compare sensitivity and positive
predictive values of fluorescence imaging with CT, MRI,
visual inspection, and LUS during laparoscopic resection
of several tumor types in the liver.
Materials and methods
Patients
The local Medical Ethics Committee and the Departments
of Surgery and Anesthesiology approved the implementa-
tion of NIR fluorescence imaging during oncologic liver
surgery as standard of care. Informed consent from all
patients was obtained. ICG (25 mg vials, Pulsion Medical
Systems, Munich, Germany) was dissolved in 10 mL
sterile water to yield a 2.5 mg/L (3.2 mM) concentration.
Subsequently, a bolus of 4 mL containing 10 mg ICG was
administered intravenously 24 h prior to surgery. Dose and
time of administration were optimized in our previous
study [8].
All patients undergoing laparoscopic staging or resec-
tion of a liver tumor were eligible for inclusion. Exclusion
criteria were eGFR \55, pregnancy, lactation, and an
allergy to iodine, shellfish, or ICG. Preoperative imaging
was performed using computed tomography (CT) with or
without positron emission tomography (PET) and in most
cases also using magnetic resonance imaging (MRI), all
within 6 weeks prior to surgery.
Near-infrared fluorescence imaging
Intraoperative imaging during surgery was performed using
the laparoscopic high-definition fluorescence imaging sys-
tem (Karl Storz GmbH & Co. KG, Tuttlingen, Germany).
The system includes a light source for visible and 760 nm
(ICG mode) light, a plasma light guide, and a 30, 10 mm
laparoscope containing optical filters. The system allows
easy switching between white light and ICG modes using a
foot pedal. Images were recorded using a charge-coupled
camera device.
Ex vivo fluorescence imaging of resected tissue speci-
mens was performed at the pathology department using the
previously described fluorescence-assisted resection and
exploration (FLARE, Beth Israel Deaconess Medical
Center, Boston, MA, USA) prototype surgical imaging
system [11]. In addition, the location of ICG in resected
tissue was assessed using fluorescence microscopy. Digital
images were made using the Leica DM5500B digital
microscope (Leica Microsystems B.V., Son, the Nether-
lands) equipped with a Leica DFC365FX camera and LAS
X software (version 2.6.0) for image acquisition and
processing.
Procedure
The procedure started with the inspection of the abdominal
cavity for the presence of extrahepatic metastases. When
none were found, the liver capsule was inspected, followed
by NIR fluorescence imaging. Subsequently, LUS was
performed by a dedicated radiologist. Each suspect lesion
detected by inspection, fluorescence imaging, and/or LUS
was resected when the surgeon considered it to be safe and
relevant.
All resected liver lesions were routinely analyzed at the
pathology department, and the method of detection was
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correlated with histopathological findings. Histopathologi-
cal diagnosis was considered the gold standard. Sensitivity
and positive predictive value of every resected lesion was
calculated for all imaging modalities. Only malignant
lesions were considered true positives. Statistical analysis
was performed using SPSS version 22.0 software (SPSS,
IBM Corporation, Somer, NY, USA).
Results
Patient characteristics
Twenty-two patients planned to undergo laparoscopic
staging (n = 4) or resection (n = 19) of one or multiple
tumors confined to the liver were included from April 2013
to November 2015. Patient characteristics are shown in
Table 1. One patient, with a suspected intrahepatic
cholangiocarcinoma, was included twice. First, he under-
went a diagnostic laparoscopy followed by resection of the
liver tumor 2 months later.
Preoperative working diagnosis differed from final
histopathological diagnosis in four patients. One patient
presented with a large, atypical mass in segments 2 and 3
was suspected to have (fibrolamellar) HCC by radiological
imaging. Final diagnosis demonstrated focal nodular
hyperplasia (FNH). The second patient, with a history of
laparoscopic cholecystectomy, presented with abdominal
pain and preoperative images showed a liver lesion suspi-
cious for HCC. This lesion was found to be liver tissue
herniated through one of the old trocar incisions. The third
patient presented with a history of breast cancer and a
FDG-PET-positive lesion in segment 4b, suspicious for
metastasis. Instead, the final diagnosis was intrahepatic
cholangiocarcinoma. The fourth patient was suspected to
have an intrahepatic cholangiocarcinoma and simultaneous
liver metastases of a non-small cell lung carcinoma
(NSCLC). The large liver tumor suspicious for cholan-
giocarcinoma was not biopsied during the first procedure.
Two other suspect lesions in the liver, either metastases of
NSCLC or hepatic adenomas, were biopsied and diagnosed
as hepatic adenomas. The large tumor was resected in a
second procedure, and final histopathological evaluation
indeed showed an intrahepatic cholangiocarcinoma.
Pre- and intraoperative tumor detection
No adverse events occurred due to ICG administration.
Two patients (suffering from UMLM and CRLM) were
excluded, because their procedure was postponed 3 and
6 days after ICG administration due to fever and logistical
reasons. This delay resulted in intraoperative fluorescence
signals too weak for sufficient guidance. In all other
patients, fluorescence imaging of all types of tumors was
successful (Fig. 1).
A total of 46 lesions, including 26 malignant tumors
with a median size of 20 mm, were resected in the
remaining 20 patients (Table 2). Sensitivity and positive
predictive values of the imaging modalities are shown in
Fig. 2. Of all resected malignancies, 20 % were missed by
CT scan, 16 % by MRI scan, 38 % by inspection, 12 % by
LUS, and 8 % by NIR fluorescence imaging. Sensitivity of
all imaging modalities of lesions sized\10 mm dropped
considerably. However, these differences were not statis-
tically significant. The lesions missed by LUS were all
superficially located. The lesions missed by intraoperative
NIR fluorescence imaging (a CRLM and UMLM) were
located [8 mm below the liver capsule. During gross
examination at the pathology department, the resected
CRLM did show rim-type fluorescence (Fig. 3). The other
false-negative lesion was located several centimeters below
the liver capsule, and diagnosis was confirmed after biopsy.
A sensitivity of 100 % was reached when fluorescence
imaging and LUS were combined.
No additional malignancies were identified only by
intraoperative inspection. LUS alone identified one addi-
tional malignant tumor (Fig. 3B). NIR fluorescence imag-
ing solely identified three additional malignancies in two
patients suffering from CRLM. The first patient presented
with a synchronous, solitary CRLM in segment 6, which
partially responded to neoadjuvant chemotherapy. During
laparoscopic metastasectomy, two additional lesions in
segment 3 were visualized by typical rim-type fluores-
cence, whereupon resection of these lesions was performed
(see Video 1 in ESM). Histopathological analysis con-
firmed the diagnosis of two metastatic intestinal-type ade-
nocarcinomas of 1 and 3 mm, respectively. The second
patient suffered from multiple CRLM resected by bi-
Table 1 Patient characteristics
Total patients, N 22




BMI, median [range] 23.0 [18.8–36.6]





Liver cirrhosis, % (n) 14 [15]
Neoadjuvant therapy, % (n) 27 [30]
Abbreviations ASA American Society of Anesthesiologists
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segmentectomy. The additional occult lesion, sized 2 mm,
was identified within the planned resection area.
Positive predictive values were 71 % (CT), 80 % (MRI),
52 % (inspection), 77 % (LUS), 75 % (NIR fluorescence
imaging), and 70 % (LUS combined with NIR fluorescence
imaging). The differences did not reach statistical signifi-
cance. Lesions that appeared suspicious by NIR fluores-
cence imaging included a bile duct hamartoma, steatotic
liver tissue, necrosis (3 times), cholestatic and inflamed
liver tissue, FNH, and a biliary adenofibroma (Fig. 4).
Other benign lesions, such as cysts and fibrosis, were
negative for NIR fluorescence. In hindsight, four benign
lesions were unnecessarily removed because inspection
alone was positive. One benign lesion was removed
because NIR fluorescence imaging alone was positive.
Fluorescence imaging resulted in clear intraoperative
demarcation of tumors. Resection could be performed more
accurately using fluorescence guidance (see Video 2 in
ESM). Prior to resection, the planned margins could be
checked again by LUS. Histopathological evaluation of all
resected malignant tumors revealed a radical resection rate
of 88 % (22/25). One large UMLM was only biopsied to
confirm diagnosis, since multiple similar liver lesions were
detected during surgery. In one patient, intraoperative NIR
fluorescence imaging after resection showed a fluorescent
margin, located on the right portal vein. LUS and inspec-
tion did not show any remaining tumor. Based on the latter
results, and the goal of preserving as much liver volume as
possible, it was decided not to extend the resection to a full
hemihepatectomy. Ex vivo evaluation of the resected tissue
Fig. 1 Representative images
of intraoperative NIR
fluorescence identification of
liver tumors. A well-
differentiated hepatocellular
carcinoma shows the uptake of
ICG in and around the tumor. A
cholangiocarcinoma shows a
rim-type fluorescence, similar to
hepatic metastasis of colorectal
and breast cancer and uveal
melanoma. As the breast cancer
and uveal melanoma liver
metastases are located below the
liver surface, the fluorescence
does not show a rim. However,
ex vivo a distinctive rim-type
fluorescence signal is visible
(data not shown). Of note, the
fluorescence laparoscope does
not possess an overlay function;
the images are therefore not
always aligned
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showed a tumor-positive resection margin, suggesting that
a full hemihepatectomy should have been considered.
In the second patient, the positive resection margin was
in retrospect visible during surgery (Fig. 5). The positive
resection margin in the third patient, suffering from a
multinodular HCC, was not visible during surgery.
Discussion
The present study describes the largest series of intraop-
erative fluorescence imaging during minimally invasive
oncological liver surgery. Laparoscopic resection of liver
tumors is believed to have several advantages over open
surgery: less intraoperative blood loss, lower morbidity
rates, and decreased length of hospital stay [12, 13].
Importantly, overall and disease-free survival remains
similar for patients with HCC and CRLM. However,
implementation of the laparoscopic technique occurs
slowly. In France for instance, currently approximately
15 % of all liver resections are performed laparoscopically
[14]. The main concerns include technical feasibility,
safety of the technique, and the substantial learning curve
[15]. Indeed, depth perception and the range of motion are
hampered by a lack of tactile feedback and three-
dimensional vision, as well as by altered orientation and
scale of the surgical field [16]. No randomized controlled
trials exist, but one can imagine that, compared to open
procedures, the more technically demanding laparoscopic
approach may expose patients to a higher risk of R1
resection. A recent meta-analysis showing a significant
lower incidence of R1 resections after laparoscopic resec-
tion of CRLM may be the result of a selection bias, as some
tumor locations with a higher risk of incomplete resection,
such as the posterior segments, make an open approach
preferable [17]. NIR fluorescence guidance during laparo-
scopic oncologic liver surgery reveals the localization of
the tumor, enhances demarcation, and hopefully results in
fewer incomplete resections. The current study showed that
no NIR fluorescence should be visible at the resection
margin to ensure a surgical margin of at least 8 mm. The
radical resection rate was 88 % (22 of 25 malignancies)
which is comparable with the literature [18]. All three
incompletely removed tumors were located in the techni-
cally more demanding segments 6, 7, and 8.
Two patients from the current study were excluded
because fluorescence imaging several days after ICG
injection resulted in fluorescence signals that were too low.
Other studies described adequate fluorescence imaging up
to 2 weeks after ICG administration [19]. Patients included
Table 2 Characteristics of
resected lesions
Histopathological diagnosis N Size (mm) Method of detection, n/Na
CT MRI Insp LUS NIRF LUS ? NIRF
Malignant
HCC 3 45 [25–58] 3/3 1/1 2/3 3/3 3/3 3/3
ChC 2 32 [30–33] 1/1 1/1 2/2 2/2 2/2 2/2
CRLM 18 18 [1–35] 14/18 11/14 10/18 15/18 17/18 18/18
UMLM 2 16 [14–18] 2/2 2/2 1/2 2/2 1/2 2/2
BCLM 1 11 0/1 1/1 1/1 1/1 1/1 1/1
Total 26 20 [1–58] 20/25 16/19 16/26 23/26 24/26 26/26
Benign
Adenoma 1 20 1/1 – 1/1 1/1 0/1 1/1
FNH 1 84 1/1 – 1/1 1/1 1/1 1/1
Biliary adenofibroma 1 18 1/1 – 1/1 1/1 1/1 1/1
Bile duct hamartoma 6 4 [2–15] 1/6 1/5 5/6 1/5 1/6 2/6
Necrosis 4 13 [8–37] 2/4 2/4 3/4 2/4 3/4 3/4
No lesion identifiedb 2 – 1/2 1/2 1/2 0/2 0/2 0/2
Otherc 5 – 1/3 0/4 3/5 1/5 2/5 3/5
Total 20 13 [2–84] 8/18 4/15 15/20 7/19 8/20 11/20
Abbreviations Insp. inspection, HCC hepatocellular carcinoma, ChC intrahepatic cholangiocarcinoma,
CRLM colorectal liver metastasis, UMLM uveal melanoma liver metastasis, BCLM breast cancer liver
metastasis, FNH focal nodular hyperplasia
a Not all lesions were imaged by all imaging modalities
b After gross examination, the pathologist could not identify any abnormal lesion in two specimens
c Includes cholestasis, cirrhotic tissue, fibrosis, and steatosis
956 Surg Endosc (2017) 31:952–961
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in these studies underwent a standard-of-care ICG clear-
ance test to assess liver function and received a dose of
0.5 mg/kg ICG. In the Netherlands, this test is not standard
of care. Moreover, we have previously optimized dose and
timing of administration resulting in a lower dose by a
factor of 3–5 [8]. The two excluded patients demonstrate
that if a procedure is postponed, adequate fluorescence
imaging demands a repeated dose of ICG, a higher initial
dose of ICG, or a more sensitive fluorescence imaging
system.
The appearance of the fluorescence signal during sur-
gery depends not only on ICG dose and timing of admin-
istration, but also on tumor type and localization.
Superficial metastases are recognizable by rim-type fluo-
rescence, while deeper located metastases are completely
surrounded by liver tissue and thus show total staining. In
the current study, ex vivo fluorescence imaging showed
rim-type fluorescence of all liver metastases and of the
intrahepatic cholangiocarcinoma, while HCC also showed
partial fluorescence. After intravenous administration, ICG
is rapidly eliminated from the blood via the liver with a
half-life of 2–3 min. Retention of ICG around liver tumors
is not only due to simple mechanical compression of bile
ducts. Recent studies revealed an underlying molecular
mechanism. The transition zone between tumor and healthy
liver tissue is composed of dedifferentiated hepatocytes
with a keratine-7-positive immature phenotype [8]. These
hepatocytes show down-regulation of anion transporters
and are consequently unable to transport ICG into biliary
canaliculi [20]. ICG is thus entrapped around tumors in
these immature hepatocytes. Normally differentiated hep-
atocytes throughout the liver have already excreted their
ICG and appear dark, just like metastases from extrahepatic
tumors and poorly differentiated HCC, resulting in high
contrast ratios. In differentiated HCC, the portal uptake
function is preserved, leading to the accumulation of ICG
in the tumor itself [21]. A similar mechanism may play a
role in ICG retention in FNH and biliary adenofibroma, as
shown in this study (Fig. 4). Observations in resected liver
tumors showed that ICG is not only preserved in fresh
tissue, but also in paraffin-embedded tissue [22]. Ex vivo
fluorescence imaging remains possible in samples as old as
3 years.
The laparoscopic imaging system used in this study, i.e.,
the Karl Storz HD fluorescence laparoscope, allows easy
switching between white light modus and fluorescence
modus using a foot pedal. A drawback of this system is that







CT 80.0 (20/25) 71.4 (20/28)
MRI 84.2 (16/19) 80.0 (16/20)
Inspection 61.5 (16/26) 51.6 (16/31)
LUS 88.5 (23/26) 76.7 (23/20)
NIRF 92.3 (24/26) 75.0 (24/32)
LUS + NIRF 100 (26/26) 70.3 (26/37)
Fig. 2 Sensitivity of all imaging modalities employed. Sensitivity
and positive predictive value of computed tomography (CT),
magnetic resonance imaging (MRI), visual inspection, laparoscopic
ultrasonography (LUS), near-infrared fluorescence imaging (NIRF),
and combination of LUS and NIRF. NIRF has the highest sensitivity
rate among all imaging modalities. Combination of NIRF ? LUS
results in the detection of all hepatic tumors (100 % detection). The
graph shows the sensitivity for all lesions together and divided into
\10 and C10 mm. Sensitivity of all imaging modalities drops
considerably for the detection of lesions\10 mm. However, all small
lesions could still be detected by combining NIRF and LUS.
Differences are not statistically significant
Surg Endosc (2017) 31:952–961 957
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available. This makes orientation during fluorescence
imaging sometimes challenging. Several other laparoscopic
fluorescence imaging systems are available, including the
commercially available Pinpoint endoscopic fluorescence
imaging system (Novadaq Technologies Inc, Toronto,
Canada) [23] and FireFly fluorescence imaging for the da
Vinci Si surgical robot (Intuitive Surgical, Inc., Sunnyvale,
CA, USA) [24]. These two systems do possess an overlay
function, which may improve ease of use.
Near-infrared light (700–900 nm) has the advantage of
higher photon penetration into tissue and lower autofluo-
rescence compared to the visible light spectrum
Fig. 3 Ex vivo fluorescence imaging of resected tumors. Rim-type
fluorescence surrounding a cholangiocarcinoma (ChC, A) and a
colorectal liver metastasis (CRLM, B) imaged using a FLARE
prototype. The CRLM was not visible using fluorescence imaging
during surgery, because it was located [8 mm below the liver
surface. Matching microscopic images (magnification 92 and 940)
of hematoxylin and eosin and DAPI staining sections were made of
ChC (C) and CRLM (D). Fluorescence shows a sharp demarcation
between normal liver tissue and fibrosis or tumor tissue. D Also
shows fluorescence in a biliary duct, probably due to mechanic
obstruction by the tumor. Abbreviations T tumor, F fibrosis, N normal
liver tissue, B biliary duct
958 Surg Endosc (2017) 31:952–961
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(400–700 nm). The reported depth penetration is however
limited to a maximum of &8 mm [25]. In the present
study, both lesions missed by fluorescence imaging were
located [8 mm below the liver surface. Although the
missed CRLM did show rim-type fluorescence ex vivo
(Fig. 3B), these lesions were intraoperatively only visible
using LUS. This finding demonstrates that fluorescence
imaging must be seen as a complementary technique to
LUS. The combination of LUS and fluorescence imaging
reached a sensitivity of 100 %. However, only suspect
lesions were resected, and this value is therefore not
accurate, just like specificity and negative predictive value.
No significant differences were found because this study
was not designed and powered to do so. Deeper located
liver tumors may also be visualized using intraoperative
photoacoustic tomography [26]. This technique combines
the specific uptake of ICG by some liver tumors with
enhanced depth penetration of ultrasonography. Although
feasible, technical improvements are required to make this
technique available for clinical use.
Multiple studies illustrated the highly sensitive intra-
operative detection of HCC and CRLM using fluorescence
Fig. 4 Fluorescence imaging of
benign lesions. A Intraoperative
imaging of a cyst (white arrow)
and a bile duct hamartoma
(dashed arrow). The cyst is not
visible using fluorescence
imaging, but the bile duct
hamartoma is. The weak
fluorescence signal does not
show a distinctive rim-type
fluorescence and can thereby be
discriminated from a
malignancy. B Benign, large
focal nodular hyperplasia also
shows NIR fluorescence. The
mechanism of ICG uptake is
unknown, but potentially its
biliary excretion is disturbed
Fig. 5 Intraoperative
visualization of a positive
resection margin of a colorectal
liver metastasis. In vivo
fluorescence is visible in the
resection margin (white arrow),
indicating a tumor-free margin
of\8 mm. Ex vivo, the
distinctive fluorescent rim is
interrupted (dashed arrow) at
the positive resection margin
Surg Endosc (2017) 31:952–961 959
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imaging [7, 8, 10, 21]. However, only one small study and
three case reports describe this technique during minimally
invasive liver surgery [9, 27–29]. Our group previously
reported the feasibility of UMLM detection in three patients
during laparoscopic resection [9]. Additional metastases
were identified in two patients. Kudo et al. showed fluo-
rescent detection of 12 out of 16 HCCs and 11 out of 16
CRLM in 17 patients [27]. Contrary to our current study, no
comparison was made between lesions detected by fluo-
rescence imaging and by other imaging modalities. More-
over, no information was provided about false-positive
lesions detected by fluorescence imaging. The rather dis-
appointing results of this study may be the result of a less
sensitive imaging system, a suboptimal ICG dose, or vari-
ations in timing of ICG administration. To improve homo-
geneity, we chose to use a fixed ICG dose and to administer
the dose the day before surgery. This strategy allowed
visualization of all included tumors in vivo or ex vivo.
Fluorescence imaging can assist in differentiating
between benign and malignant lesions, such as cysts,
fibrosis, and hemangiomas. In the current study, four
necrotic lesions were suspicious using fluorescence imag-
ing. These lesions were resected in two CRLM patients
who received neoadjuvant therapy. It may be that these
lesions were in fact tumors that fully responded to the
chemotherapy. In addition, two other resected lesions (a
biliary adenofibroma and FNH) were considered false-
positive, because they were benign. Nonetheless, imaging
of these large lesions (18–84 mm) was still relevant as
these lesions were preoperatively planned to be resected.
Other studies describing fluorescence imaging during
laparoscopic resection of liver tumors do not mention false-
positivity rates.
Three occult, otherwise undetected, liver tumors (12 %)
were identified in two patients suffering from CRLM.
Other studies describe similar results. van der Vorst et al.
[8] identified additional lesions in 12.5 % (5 of 40) of
patients suffering from CRLM. Ishizawa et al. [21]
examined resected liver specimens of patients with HCC
and identified 7.7 % (21 of 273) additional HCCs that were
not identified by gross examination. A key unanswered
question is whether these additional lesions are ‘‘harbin-
gers’’ of even more tumors not yet visible by any means or
the only sites of disease that would otherwise have not been
resected. One patient in the current study developed mul-
tiple liver metastases 3 months after surgery. The second
patient is still disease-free after 6 months. Of the five
patients with additional detected tumors in the study of van
der Vorst et al. [8], two developed hepatic recurrence
within 1 year, but three are currently still disease-free after
a period of 3–6 years. Although these results should be
interpreted cautiously, it appears that NIR fluorescence
imaging can indeed prevent recurrence in some patients.
This study demonstrates the added value of intraopera-
tive navigation using NIR fluorescence imaging during
laparoscopic resection of a broad variety of malignant liver
tumors. It is an easy, effective, and safe method. NIR flu-
orescence imaging can assist in localization and demarca-
tion of known tumors, as well as identification of otherwise
undetectable occult liver tumors. Large studies are required
to confirm whether fluorescence-guided resection of liver
tumors can improve radical resection rates and patient
outcomes, but based on our results, we believe this method
could quickly be an important component of laparoscopic
resection of liver tumors.
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